163 related articles for article (PubMed ID: 11641415)
1. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.
Smith V; Raynaud F; Workman P; Kelland LR
Mol Pharmacol; 2001 Nov; 60(5):885-93. PubMed ID: 11641415
[TBL] [Abstract][Full Text] [Related]
2. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
Incles CM; Schultes CM; Kelland LR; Neidle S
Mol Pharmacol; 2003 Nov; 64(5):1101-8. PubMed ID: 14573759
[TBL] [Abstract][Full Text] [Related]
3. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI
Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540
[TBL] [Abstract][Full Text] [Related]
7. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer.
Chien M; Astumian M; Liebowitz D; Rinker-Schaeffer C; Stadler WM
Cancer Chemother Pharmacol; 1999; 44(1):81-7. PubMed ID: 10367753
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Jung CP; Motwani MV; Schwartz GK
Clin Cancer Res; 2001 Aug; 7(8):2527-36. PubMed ID: 11489836
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.
Smith V; Rowlands MG; Barrie E; Workman P; Kelland LR
Clin Cancer Res; 2002 Jun; 8(6):2002-9. PubMed ID: 12060646
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells.
Schrump DS; Matthews W; Chen GA; Mixon A; Altorki NK
Clin Cancer Res; 1998 Nov; 4(11):2885-90. PubMed ID: 9829756
[TBL] [Abstract][Full Text] [Related]
15. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
[TBL] [Abstract][Full Text] [Related]
16. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.
Camphausen K; Brady KJ; Burgan WE; Cerra MA; Russell JS; Bull EE; Tofilon PJ
Mol Cancer Ther; 2004 Apr; 3(4):409-16. PubMed ID: 15078984
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
Mayer F; Mueller S; Malenke E; Kuczyk M; Hartmann JT; Bokemeyer C
Invest New Drugs; 2005 Jun; 23(3):205-11. PubMed ID: 15868376
[TBL] [Abstract][Full Text] [Related]
19. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of action of flavopiridol.
Sedlacek HH
Crit Rev Oncol Hematol; 2001 May; 38(2):139-70. PubMed ID: 11311660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]